Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Murati

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
British Journal of Haematology|October 1, 2010
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemiaVéronique Gelsi-Boyer, Virginie Trouplin, Julien Roquain, et al.
Genes, Chromosomes & Cancer|June 12, 2003
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 geneJosé Adélaïde, Huai-En Huang, Anne Murati, et al.
Acta Haematologica|June 15, 2026
Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter studyEdmond Chiche, Caroline Fileni, Sarah Bonnet, et al.
American Journal of Hematology|May 29, 2015
Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosisCharles Herbaux, Nicolas Duployez, Catherine Badens, et al.
European Journal of Haematology|August 12, 2024
Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogeneticsAmel Soua, Julia Gilhodes, Alexandre Iat, et al.
British Journal of Haematology|November 12, 2019
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progressionLaurane Cottin, Jérémie Riou, Corentin Orvain, et al.
Blood Advances|October 9, 2020
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformationDamien Luque Paz, Rébecca Jouanneau-Courville, Jérémie Riou, et al.
American Journal of Hematology|February 26, 2024
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHMLaura Aubin, Rúben Vilas Boas, Rafael Daltro De Oliveira, et al.
Blood Advances|March 5, 2021
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM studyDamien Luque Paz, Jérémie Riou, Emmanuelle Verger, et al.
Leukemia|April 1, 2025
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric studyLucile Bussot, Stéphanie Poulain, Morgane Nudel Ortmans, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
British Journal of Haematology|October 1, 2010
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemiaVéronique Gelsi-Boyer, Virginie Trouplin, Julien Roquain, et al.
Genes, Chromosomes & Cancer|June 12, 2003
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 geneJosé Adélaïde, Huai-En Huang, Anne Murati, et al.
Acta Haematologica|June 15, 2026
Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter studyEdmond Chiche, Caroline Fileni, Sarah Bonnet, et al.
American Journal of Hematology|May 29, 2015
Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosisCharles Herbaux, Nicolas Duployez, Catherine Badens, et al.
European Journal of Haematology|August 12, 2024
Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogeneticsAmel Soua, Julia Gilhodes, Alexandre Iat, et al.
British Journal of Haematology|November 12, 2019
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progressionLaurane Cottin, Jérémie Riou, Corentin Orvain, et al.
Blood Advances|October 9, 2020
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformationDamien Luque Paz, Rébecca Jouanneau-Courville, Jérémie Riou, et al.
American Journal of Hematology|February 26, 2024
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHMLaura Aubin, Rúben Vilas Boas, Rafael Daltro De Oliveira, et al.
Blood Advances|March 5, 2021
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM studyDamien Luque Paz, Jérémie Riou, Emmanuelle Verger, et al.
Leukemia|April 1, 2025
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric studyLucile Bussot, Stéphanie Poulain, Morgane Nudel Ortmans, et al.
Pageof 4